

# Index

- aberrant immunophenotypes in acute myeloid leukaemias, 172–81  
 application of LAIPs, 179–80  
 LAIP definition, 179  
 MRD, expressing, 181  
 subjectivity in, 173–9  
 types of, 172–3
- acute leukaemia, immunophenotypic features  
 acute lymphoblastic leukaemias, 81–7  
 acute myeloid leukaemia not otherwise specified, 79–81  
 introduction to, 75  
 recurrent genetic abnormalities, 75–9
- acute lymphoblastic leukaemias (ALL), 81–7, 89  
 antigens for lineage assessment, 91–2  
 B-cell progenitor (BCP) acute lymphoblastic leukaemia (B-I), 82  
 common B-ALL B-II, 82  
 cortical T-acute lymphoblastic leukaemia (T-III), 85–6  
 diagnosis, 89–91  
 diagnosis by immunophenotyping, 90  
 DNA index (DI), 99–101  
 early T-precursor (ETP) T-acute lymphoblastic leukaemia (T-I), 84  
 genetic recurrent abnormalities, 92–6  
 mature T-acute lymphoblastic leukaemia (T-IV), 86–7  
 Minimal Residual Disease (MRD) detection, 96–9  
 pre B ALL- B-III, 82–4  
 report, 92  
 T-acute lymphoblastic leukaemia (T-II), 84–5
- acute lymphoid leukaemias, minimal residual disease. *See* Minimal Residual Disease (MRD) detection
- acute myeloid leukaemias, 75–9  
 acute promyelocytic leukaemia (APL), 75–6  
 acute promyelocytic leukaemia variant (APLv), 76–7  
 not otherwise specified, 79–81  
 with inv(16) or t(16;16) translocation, 77–8  
 with maturation, 79–80  
 with minimal differentiation, 79  
 with monocytic differentiation, 80–1  
 with NPM1 mutation, 78  
 with t(8;21) translocation, 77  
 without maturation, 79
- acute myeloid leukaemias, minimal residual disease in, 171–86  
 aberrant immunophenotypes, 172–81  
 as measure of effectiveness of therapies, 182  
 biased group choices, 183  
 blast reduction, 182–3  
 clinical applications, 181–2  
 conclusions, 186  
 cytogenetic, mutational, and immunophenotypical changes, 185–6  
 false negatives, 183–4  
 false positives, 184  
 immunophenotypic MRD, 172  
 in allogeneic transplantation, 181–2  
 introduction to, 171–2  
 leukaemia stem cell load, 184  
 overlooked issues, 182–4  
 PB MRD, 182  
 risk stratification, 181
- acute promyelocytic leukaemia (APL), 75–6  
 acute promyelocytic leukaemia variant (APLv), 76–7  
 adult T-cell leukaemia/lymphoma, 146–7  
 aggressive B-cell lymphomas, 118–20  
 Burkitt's lymphoma (BL), 118–19  
 diffuse large B-cell lymphoma (DLBCL), 118  
 high grade B-cell lymphoma, 119–20  
 aggressive NK cell leukaemia (ANKL), 153–4  
 ambiguous lineage acute leukaemia (AUL). *See* mixed phenotype acute leukaemias (MPALs)
- anaemia associated with chronic disease (ACD), 71  
 analogic/digital converters (ADC), 4  
 angioimmunoblastic T-cell lymphoma, 149  
 antigen expression patterns in normal blood, 36–7
- antigens  
 differentiation antigen families, 28  
 immature cell antigens, 15–16  
 introduction to, 14–15  
 lymphoid antigens, 22–7  
 myeloid antigens, 17–22  
 others of relevance, 26–31
- aplastic anaemia (AA), 66–8  
 applications for diagnostic and prognostic immunophenotyping, 133–8  
 flow cytometry to myeloma MRD, applicability of, 135
- international consensus, importance of, 135–7  
 minimal residual disease analysis, 134–5  
 MRD analysis by flow cytometry, 137–8  
 normal vs. neoplastic plasma cells, proportion of, 133–4  
 phenotypic characteristics with prognostic significance, 134  
 plasmacytoma, staging of, 134  
 therapeutic targets, identification and quantitative assessment, 134  
 autoimmune thrombocytopenia (AIT), 70–1  
 automated analysis, software for, 222–5
- basophils, 45–6, 62  
 B-cell lymphoproliferative disorders (LPD), 61  
 B-cell progenitor (BCP) acute lymphoblastic leukaemia (B-I), 82  
 B-cell prolymphocytic leukaemia (B-PLL), 111  
 B-cells, 49–50  
 immunphenotypic aberrancies, 64  
 B-cells, immunophenotype of, 43  
 BCR-ABL  
 t(9;22) translocation, 95  
 Bernard Soulier syndrome, 22  
 Beta-2 integrins, 17  
 biparametric histograms, 5–6, 5, 7  
 blast reduction, 182–3  
 blastic plasmacytoid dendritic cell neoplasm (BPDCN), 81  
 B-lineage antigens, 22–4  
 blood, antigen expression patterns in, 36–7  
 Blood-derived Dendritic Cell Antigens (BDCA), 20  
 BM cells, 69–70  
 bone marrow  
 immature cells, 47  
 lymphocyte differentiation in, 49–51  
 normal subpopulations, 47  
 subsets, 51–3  
 Burkitt's lymphoma (BL), 118–19
- CD1, 25  
 CD1a, 26  
 CD2, 24, 25  
 CD3, 25, 24–5  
 CD4, 25  
 CD5, 25  
 CD7, 25, 26  
 CD8, 25

## Index

- CD9, 24  
 CD10, 15, 24  
 CD13, 17, 18  
 CD14, 18, 19  
 CD15, 17  
 CD16, 17, 19, 26, 27  
 CD19, 22, 23  
 CD20, 22, 23  
 CD21, 22, 23  
 CD22, 22, 23  
 CD23, 22, 23  
 CD24, 22, 23  
 CD25, 26–7  
 CD26, 28  
 CD27, 28  
 CD28, 28  
 CD30, 28  
 CD32, 18, 19  
 CD33, 17, 18  
 CD34, 15–16  
 CD35, 20, 21  
 CD36, 18, 19, 21, 22  
 CD38, 15, 16–17  
 CD40, 28–9  
 CD41, 21  
 CD42, 21  
 CD42b, 21  
 CD43, 15, 29  
 CD45, 15  
 CD49, 29  
 CD54, 29  
 CD56, 26, 27  
 CD57, 26, 27  
 CD58, 29  
 CD60, 29  
 CD61, 21  
 CD64, 18, 19  
 CD65, 17  
 CD66, 29  
 CD71, 20  
 CD79, 22  
 CD79a, 23  
 CD79b, 23  
 CD81, 22–4  
 CD86, 29  
 CD91, 18, 29  
 CD94, 26, 27  
 CD95, 29–30  
 CD105, 21, 20–1  
 CD117, 16, 17–18  
 CD123, 20  
 CD133, 16  
 CD135, 30  
 CD138, 23, 24  
 CD148, 30  
 CD152, 30  
 CD158, 26  
 CD160, 26, 27  
 CD161, 26, 27  
 CD163, 18, 30  
 CD164, 16  
 CD180, 30  
 CD194, 30  
 CD197, 30  
 CD200, 30  
 CD229, 30
- CD235, 21  
 CD241, 21  
 CD278, 30–1  
 CD279, 31  
 CD300e, 31  
 CD303, 18  
 CD304, 18  
 CD317, 31  
 CD319, 31  
 CD371, 31
- chronic lymphocytic leukaemia (CLL), 61  
 chronic lymphocytic leukaemia/small  
   lymphocytic lymphoma (CLL/SLL),  
   107–11  
   minimal residual disease detection in, 111  
 chronic lymphoproliferative disorders of  
   natural killer-cells (CLPDNK),  
   151–3  
 classical Hodgkin lymphoma (CHL).  
   *See* Hodgkin lymphoma, flow  
   cytometric diagnosis  
 clonal haematopoiesis of indeterminate  
   potential (CHIP), 71  
 clonality, assessment of, 133  
 closed hands-off instruments, 220  
 clusters of differentiation (CD), 14–15  
 common B-ALL B-II, 82  
 compact dedicated instruments, 219–20  
   compensation, 7, 10  
 complete remission (CR), 96  
 cortical T- acute lymphoblastic leukaemia  
   (T-III), 85–6  
 CRLF2 rearrangements, 96  
 CytoDiff<sup>®</sup> reagent, 36  
 CyTOF (cytometry by time of flight), 216–19  
 cytokines and other proteins, 220  
 cytometry, 1  
 cytopenias, 66–72
- dendritic cell antigens, 20  
 dendritic cells (DCs), 46, 53  
 diagnostic immunophenotyping,  
   applications for, 133–8  
 differentiation antigen families, 28  
 diffuse large B-cell lymphoma (DLBCL), 118  
 DNA index (DI), 99–101  
 dysmegakaryopoiesis, 206
- early myeloid antigens, 17–18  
 early T-precursor (ETP) T- acute  
   lymphoblastic leukaemia (T-I), 84  
 emission spectra, 7  
 eosinophils, 45, 62  
 erythroid antigens, 20–1  
 erythroid lineage, 206  
 erythropoietic differentiation, 48–9  
 Ethylene Diamine Tetraacetic Acid  
   (EDTA), 10  
 event free survival (EFS), 89  
 extranodal NK/T-cell lymphoma (NKTCL),  
   153–4
- FCM assay  
   development for Hodgkin lymphoma, 163  
   gating strategy, 163–6  
   reagent selection, 163–6
- fluorochemicals, 3–4  
 flow cytometry (FCM). *See also* Hodgkin  
   lymphoma, flow cytometric  
   diagnosis  
   advantage of, 1  
   and fluorochemicals, 3–4  
   and light, 2–3  
   cell counting in, 1–2  
   compensation, 7, 10  
   conclusions, 11–12  
   conditions/diseases that mimic  
   haematological malignancies, 61–72  
   flow component of, 1  
   in myelodysplastic syndromes (MDS),  
   199–211  
   introduction to, 1  
   Nodular lymphocyte predominant HL,  
   167–8  
   panel design, 10  
   post-analytical procedures, 11–12  
   sample handling, 10–11  
   settings, 7–10  
   signal acquisition, 4  
   signals displays, 4–7  
   T-cell receptor clonality, assessment by,  
   142  
 flow cytometry (FCM) of normal blood,  
   bone marrow, and lymphatic tissue  
   antigen expression patterns in normal  
   blood, 36–7  
   bone marrow cell subpopulations, 47  
   bone marrow subsets, 51–3  
   conclusions, 56  
   erythropoietic differentiation, 48–9  
   granulocytic differentiation, 47–8  
   immature cells of bone marrow, 47  
   introduction to, 36  
   lymphocyte differentiation in bone  
   marrow, 49–51  
   lymphocytes, 37–45  
   lymphoid organs, normal patterns in  
   immunophenotyping, 53–6  
   minor blood cell subsets, 45–7  
   monocytic differentiation, 48
- flow cytometry (FCM), future applications  
   of, 215–28  
   automated analysis, software for, 222–5  
   closed hands-off instruments, 220  
   compact dedicated instruments, 219–20  
   conclusions, 228  
   CyTOF (cytometry by time of flight),  
   216–19  
   cytokines and other proteins, 220  
   flow epigenetics, 222  
   ImageStream<sup>®</sup>, 215–16  
   introduction to, 215  
   microfluidics, 220  
   new software, 225–8  
   phospho flow, 220–2  
   spectral flow cytometry, 216
- flow cytometry to myeloma MRD,  
   applicability of, 135  
 flow epigenetics, 222  
 Fluorescence Resonance Energy Transfer  
   (FRET), 4  
 fluorochemicals, 3–4

- follicular lymphoma (FL), 115–16  
forward scatter (FSC), 2
- gate statistics, 6  
gating hierarchy, 6  
gating strategy, 6  
Gaussian clusters, 6  
genetic recurrent abnormalities, 92–6  
  BCR-ABL  
    t(9;22) translocation, 95  
  CRLF2 rearrangements, 96  
  MLL/KMT2A  
    11q23 rearrangements, 95  
  phenotype Switching-ALL, 96  
  TEL/AML1  
    t(12;21) translocation, 95–6  
Glanzmann's thrombasthenia, 22  
granulocytic antigens, 19–20  
granulocytic compartment, aberrancies in, 202–5  
granulocytic differentiation, 47–8
- haematopoietic stem cell (HSC), 15  
haemodilution, 68–9  
haemodilution of bone marrow samples, 10  
hairy cell leukaemia (HCL), 113  
hairy cell leukaemia variant (HCL-v), 113–14  
HematoFlow® system, 36  
heparin, 10  
hepatosplenic T-cell lymphoma, 149–50  
high grade B-cell lymphoma, 119–20  
HLA-DR, 16, 19  
Hodgkin lymphoma, flow cytometric diagnosis, 161–9  
  conclusions/future directions, 168–9  
  FCM assay, development of, 163  
  gating strategy, 163–6  
  immunophenotype of HRS cells, 161–3  
  inflammatory background, diagnostic utility of, 167  
  introduction to, 161  
  Nodular lymphocyte predominant HL, flow cytometry of, 167–8  
  potential immunophenotypic and morphologic confounders, 166  
  reagent selection, 163–6  
Human Leukocyte Differentiation Antigens (HLDA) conferences, 14
- idiopathic cytopenia of undetermined significance (ICUS), 71  
ImageStream®, 215–16  
immature cell antigens, 15–16  
immature cells, 63–4  
immunophenotype, of HRS cells, 161–3  
immunophenotypic aberrancies, 64–6  
immunophenotypic patterns, 11  
indolent B-cell lymphomas, 107–18  
  B-cell prolymphocytic leukaemia (B-PLL), 111  
  chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL), 107–11  
  follicular lymphoma (FL), 115–16  
  hairy cell leukaemia (HCL), 113  
  hairy cell leukaemia variant (HCL-v), 113–14  
  lymphoplasmacytic lymphoma (LPL), 114–15  
  mantle cell lymphoma (MCL), 116–18  
  marginal zone lymphoma (MZL), 111–13  
  minimal residual disease detection in CLL, 111  
  splenic diffuse red pulp small B-cell lymphoma, 114  
inflammatory background, diagnostic utility of, 167
- Killer Immunoglobulin-like Receptors (KIRs), 26  
KIR families, 27  
Köhler, George, 14
- leucocytosis, 61–4  
leukaemia stem cell load, 184  
light  
  and flow cytometry, 2–3  
  and fluorochromes, 4  
lymph nodes, 53  
lymphocyte differentiation  
  B-cells, 49–50  
  in bone marrow, 49–51  
  natural killer (NK)-cells, 51  
  plasma cells, 51  
  T-cells, 51  
lymphocytes, 37–45  
  B-cells, immunophenotype of, 43  
  monocytes, immunophenotype of, 45  
  natural killer (NK)-cells, 45  
  neutrophil granulocytes, immunophenotype of, 45  
  reference values, 37–43  
  T-cells, immunophenotype of, 43–5  
lymphocytosis, 61  
lymphoid antigens, 22–7  
  B-lineage antigens, 22–4  
  natural killer (NK)-cells' antigens, 26  
  T lineage antigens, 24–6  
lymphoid organs  
  body fluids, 55–6  
  lymph nodes and tonsils, 53  
  normal patterns in immunophenotyping, 53–6  
  spleen, 53–5  
  thymus, 55  
lymphoplasmacytic lymphoma (LPL), 114–15  
lymphoproliferative disorders (LPD), 61  
lysing reagents, 11
- mantle cell lymphoma (MCL), 116–18  
marginal zone lymphoma (MZL), 111–13  
mast cells, 51–3  
mature B-cell lymphomas, immunophenotyping of, 105–20  
  aggressive B-cell lymphomas, 118–20  
  indolent B-cell lymphomas, 107–18  
  introduction to, 105–7  
mature granulocytic compartment, 66  
mature T-acute lymphoblastic leukaemia (T-IV), 86–7  
mature T-cell neoplasms, 140–55  
  antibody panels for, 140–2  
  conclusions, 154–5  
  introduction to, 140  
  T-cell lymphoproliferative disorders, 142–51  
  T-cell receptor clonality, assessment by flow cytometry analysis, 142  
maturing myeloid cell populations, 66  
May Grünwald Giemsa (MGG), 1  
merge function, 7  
microfluidics, 220  
minimal residual disease (MRD)  
  acute myeloid leukaemias, 171–86  
  analysis of, 134–5  
  by flow cytometry, 137–8  
  detection of in CLL, 111  
Minimal Residual Disease (MRD)  
  detection, 96–9. *See also* acute lymphoblastic leukaemias (ALL)  
  introduction to, 89  
mixed phenotype acute leukaemias (MPALs), 191–8  
  B-lineage, 193  
  diagnosing, 192  
  diagnosis, proposed panels for, 194–8  
  introduction to, 191–2  
  myeloid lineage, 193  
  scoring and diagnosis, recommendations for, 192–3  
  subtypes of, 193–4  
  T lineage, 193  
MLL/KMT2A  
  11q23 rearrangements, 95  
monoclonal antibodies (MAbs), 14  
monocytes, immunophenotype of, 45  
monocytic differentiation, 48  
monocytic lineage, aberrancies in, 205–11  
  clinicians, reporting to, 210  
  diagnostic scores in MDS, 206–10  
  dysmegakaryopoiesis, 206  
  erythroid lineage, 206  
  mycosis fungoides, 147–9  
  myelodysplastic syndromes (MDS), 66, 70  
  myelodysplastic syndromes (MDS), flow cytometry in, 199–211  
  clinicians, reporting to, 210  
  diagnostic scores, 206–10  
  granulocytic compartment, aberrancies in, 202–5  
  introduction to, 199–200  
  monocytic lineage, aberrancies in, 205–11  
  myeloid progenitor cells, aberrancies in, 201–3  
  practical considerations, 200–1  
  treatment strategies/disease monitoring, 211  
myeloid antigens, 17–22  
  dendritic cell antigens, 20  
  early myeloid antigens, 17–18  
  erythroid antigens, 20–1  
  major differentiation antigens of monocytes and dendritic cells, 18  
  major myeloid differentiation antigens, 17  
  myelomonocytic antigens, 19  
  other granulocytic antigens, 19–20  
  thrombocytic antigens, 21–2

## Index

- myeloid leukaemias, 75–9  
myeloid progenitor cells, aberrancies in, 201–3  
myeloid-derived suppressor cells (MDSCs), 47  
myelomonocytic antigens, 19
- natural killer (NK)-cells, 45, 51  
antigens, 26  
natural killer-cell (NK) lymphoproliferative disorders, 151–4  
aggressive NK cell leukaemia (ANKL), 153–4  
chronic lymphoproliferative disorders of natural killer-cells (CLPDNK), 151–3  
extranodal NK/T-cell lymphoma (NKTCL), 153–4  
neoplastic plasma cell immunophenotype, 132–3  
neutrophil granulocytes, immunophenotype of, 45  
neutrophilia, 62  
NK-cell malignancies, 140–55  
antibody panels for, 140–2  
conclusions, 154–5  
introduction to, 140  
natural killer-cell (NK) lymphoproliferative disorders, 151–4  
Nodular lymphocyte predominant HL, flow cytometry of, 167–8  
non-malignant conditions  
cytopenias, 66–72  
immunophenotypic aberrancies, 64–6  
introduction to, 61  
leucocytosis, 61–4  
summary, 72  
normal plasma cell immunophenotype, 131  
normal vs. neoplastic plasma cells, proportion of, 133–4
- panel design, 10  
paroxysmal nocturnal haemoglobinuria (PNH), 68  
phenotype Switching-ALL, 96  
phospho flow, 220–2  
photodiode or photomultiplier (PMT), 2, 7  
plasma cell analysis, 129–33  
clonality, assessment of, 133  
neoplastic plasma cell immunophenotype, 132–3  
normal plasma cell immunophenotype, 131  
plasma cell gating, 129–31  
sample preparation, 129  
sample quality, 129  
plasma cell gating, 129–31  
plasma cell myeloma, 128–38  
analysis, technical aspects of, 129–33  
applications for diagnostic and prognostic immunophenotyping, 133–8  
description of, 128  
related conditions, 129  
plasma cells, 51  
plasmacytoma, staging of, 134  
plasmacytosis, 62  
pre B ALL- B-III, 82–4  
prognostic immunophenotyping, applications for, 133–8
- regenerative BM, 70
- Sézary syndrome, 147–9  
sheath fluid, 9  
side scatter (SSC), 2  
signal acquisition, 4  
signals displays, 4–7  
spectral flow cytometry, 216  
spleen, 53–5  
splenic diffuse red pulp small B-cell lymphoma, 114
- T-acute lymphoblastic leukaemia (T-II), 84–5  
T lineage antigens, 24–6  
T-cell and NK-cell lymphoproliferative diseases (T-NK-CLPD), antibody panels for, 140–2  
T-cell large granular lymphocytic leukaemia, 150–1  
T-cell lymphoproliferative disorders, 142–51  
adult T-cell leukaemia/lymphoma, 146–7  
angioimmunoblastic T-cell lymphoma, 149  
hepatosplenic T-cell lymphoma, 149–50  
mycosis fungoides, 147–9  
Sézary syndrome, 147–9  
T-cell large granular lymphocytic leukaemia, 150–1  
T-cell prolymphocytic leukaemia, 142–6  
T-cell prolymphocytic leukaemia, 142–6  
T-cell receptor clonality, assessment by flow cytometry analysis, 142  
T-cells, 51  
immunophenotypic aberrancies, 65–6  
lymphocytosis, 61–2  
T-cells, immunophenotype of, 43–5  
TEL/AML1 t(12;21) translocation, 95–6  
therapeutic targets, identification and quantitative assessment, 134  
thymus, 55  
Tonegawa, Susumu, 14  
tonsils, 53  
toxic effect of drugs, 69–70
- ulcerative colitis, 70
- Wright stains, 1